Advertisement

 

 

Immunotherapy for pancreatic cancer: A long and hopeful journey.

Immunotherapy for pancreatic cancer: A long and hopeful journey.
Author Information (click to view)

Xu JW, Wang L, Cheng YG, Zhang GY, Hu SY, Zhou B, Zhan HX,


Xu JW, Wang L, Cheng YG, Zhang GY, Hu SY, Zhou B, Zhan HX, (click to view)

Xu JW, Wang L, Cheng YG, Zhang GY, Hu SY, Zhou B, Zhan HX,

Advertisement

Cancer letters 2018 03 29() pii S0304-3835(18)30243-X
Abstract

Multiple therapeutic strategies have been developed to treat pancreatic cancer. However, the outcomes of these approaches are disappointing. Due to deeper understandings of the pivotal roles of the immune system in pancreatic cancer tumorigenesis and progression, novel therapeutic strategies based on immune cells and the tumor microenvironment are being investigated. Some of these approaches, such as checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and BiTE antibodies, have achieved exciting outcomes in preclinical and clinical trials. The current review describes the roles of immune cells and the immunosuppressive microenvironment in the development of pancreatic cancer, as well as the preclinical and clinical outcomes and benefits and considerations of recent passive and active immunotherapeutic approaches, which may help us further disclose the mechanisms of pancreatic cancer progression and the dialectical views of feasibility and effectiveness of immunotherapy in treatment of pancreatic cancer.

Submit a Comment

Your email address will not be published. Required fields are marked *

19 − 2 =

[ HIDE/SHOW ]